RBC Capital analyst Douglas Miehm raised the firm’s price target on Aurinia Pharmaceuticals to $13 from $11 and keeps an Outperform rating on the shares ahead of its Q1 results this week. The firm is reducing the weighting of the negative scenario for LUPKYNIS – the loss of exclusivity in 2027 – from 25% to 10% given the newly issued method-of-use patent that should support exclusivity until 2037, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AUPH:
- AUPH Earnings this Week: How Will it Perform?
- Aurinia Pharmaceuticals call volume above normal and directionally bullish
- Biotech Alert: Searches spiking for these stocks today
- Cantor says Aurinia M&A takeout chatter ‘picks back up’ after MKT letter
- MKT Capital to withhold director support, says Aurinia should explore sale
